Andrew R. Reynolds
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Angiogenesis and VEGF in Cancer, Renal cell carcinoma treatment, Cancer, Hypoxia, and Metabolism, MRI in cancer diagnosis, Cell Adhesion Molecules Research
Most-Cited Works
- → Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions(2014)723 cited
- → Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors(2009)476 cited
- → Vessel co-option in cancer(2019)436 cited
- → Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases(2016)425 cited
- → ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A(2016)379 cited
- → Quantitative Imaging of Lateral ErbB1 Receptor Signal Propagation in the Plasma Membrane(2000)347 cited
- → Activation of PPARβ/δ Induces Endothelial Cell Proliferation and Angiogenesis(2006)239 cited
- → EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation(2003)235 cited
- → The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications(2013)221 cited
- → Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models(2016)208 cited